Preclinical Lead Compounds

About Gabather

Gabather's mission is to develop transformative medicines for neuropsychiatric disorders by targeting the brain's major inhibitory system, the GABA-A receptor. The company has achieved key milestones with its lead candidate, GT-002, a pro-cognitive modulator that has demonstrated safety, tolerability, and excellent pharmacokinetics in Phase I trials. Its strategy centers on using a unique drug discovery engine and early human target engagement studies to accelerate the development of novel treatments for conditions like Alzheimer's disease, schizophrenia, and major depressive disorder.

Therapeutic Areas

Other Undisclosed CNS Indications Drugs